SRR8518381
— · A
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- A
- subtype
- A
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- ESTROGEN_RESPONSE_EARLY+0.360
- UV_RESPONSE_DN+0.350
- MYOGENESIS+0.270
- BILE_ACID_METABOLISM+0.230
- TGF_BETA_SIGNALING+0.230
- ESTROGEN_RESPONSE_LATE+0.170
- APICAL_SURFACE+0.150
- COAGULATION+0.130
- FATTY_ACID_METABOLISM+0.120
- KRAS_SIGNALING_UP+0.110
Top 10 suppressed
- E2F_TARGETS-0.690
- MYC_TARGETS_V2-0.680
- MYC_TARGETS_V1-0.630
- G2M_CHECKPOINT-0.590
- MTORC1_SIGNALING-0.520
- UNFOLDED_PROTEIN_RESPONSE-0.460
- GLYCOLYSIS-0.400
- DNA_REPAIR-0.380
- OXIDATIVE_PHOSPHORYLATION-0.370
- INTERFERON_ALPHA_RESPONSE-0.340
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
10 twins match this tumor's tissue · 0 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | SRR8613705 | — | A | 0.928 |
| 2 | TCGA-GD-A3OP-01A-21R-A220-07 | — | — | 0.899 |
| 3 | SRR8613714 | — | A | 0.895 |
| 4 | C3L-01890 | — | cohortA2 | 0.892 |
| 5 | TCGA-44-6148-01A-11R-1755-07 | — | cohortA1 | 0.884 |
| 6 | SRR10900010 | — | — | 0.882 |
| 7 | SRR8613701 | — | A | 0.874 |
| 8 | TCGA-50-5942-01A-21R-1755-07 | — | cohortA1 | 0.874 |
| 9 | GSM6454739 | — | A | 0.866 |
| 10 | TCGA-AC-A8OS-01A-12R-A41B-07 | — | A | 0.865 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 16 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| ESTROGEN_RESPONSE_EARLY | 0.360 | Inavolisib | — uncovered |
| UV_RESPONSE_DN | 0.350 | Inavolisib | — uncovered |
| MYOGENESIS | 0.270 | Inavolisib | — uncovered |
| BILE_ACID_METABOLISM | 0.230 | Inavolisib | — uncovered |
| TGF_BETA_SIGNALING | 0.230 | Inavolisib | — uncovered |
| ESTROGEN_RESPONSE_LATE | 0.170 | Idelalisib | — uncovered |
| APICAL_SURFACE | 0.150 | Temsirolimus | — uncovered |
| COAGULATION | 0.130 | Binimetinib | — uncovered |
| FATTY_ACID_METABOLISM | 0.120 | Inavolisib | — uncovered |
| KRAS_SIGNALING_UP | 0.110 | Inavolisib | — uncovered |
| APICAL_JUNCTION | 0.100 | Inavolisib | — uncovered |
| XENOBIOTIC_METABOLISM | 0.100 | Inavolisib | — uncovered |
| ADIPOGENESIS | 0.070 | Inavolisib | — uncovered |
| ANGIOGENESIS | 0.010 | Remibrutinib | — uncovered |
| HEDGEHOG_SIGNALING | 0.010 | Inavolisib | — uncovered |
| PEROXISOME | 0.010 | Idelalisib | — uncovered |